Search Results - "Riddle, M.C."

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in insulin- naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial by Bolli, G.B, Riddle, M.C, Bergenstal, R.M, Wardecki, M, Goyeau, H, Home, P.D

“…Abstract Aim To explore if efficacy and safety findings for insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100), observed over…”
Get full text

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension) by Terauchi, Y, Koyama, M, Cheng, X, Sumi, M, Riddle, M.C, Bolli, G.B, Hirose, T

“…Abstract Aims To compare insulin glargine 300 U/mL (Gla-300) with glargine 100 U/mL (Gla-100) in Japanese adults with uncontrolled type 2 diabetes on basal…”
Get full text

Reply to the Letter to the Editor: Response to Concerns Raised on MRI Surveillance and Clinical Implications of ARIA in Disease Modifying Treatment by Howe, M D, Riddle, M C, Salloway, S P

Get full text

Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial by Ferrannini, G, Gerstein, H.C, Colhoun, H.M, Dagenais, G.R, Diaz, R, Dyal, L, Lakshmanan, M, Mellbin, L, Probstfield, J, Riddle, M.C, Shaw, J.E, Ryden, L

“…Abstract Background The 2019 ESC/EASD European Guidelines for Diabetes, Prediabetes and Coronary Artery Disease introduced a paradigm shift in the management…”
Get full text

Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial by Bolli, G.B., Riddle, M.C., Bergenstal, R.M., Wardecki, M., Goyeau, H., Home, P.D.

“…To explore if efficacy and safety findings for insulin glargine 300U/mL (Gla-300) versus insulin glargine 100U/mL (Gla-100), observed over 6 months in…”
Get full text

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events by Riddle, M.C., Bolli, G.B., Avogaro, A., Gimenez Álvarez, M., Merino-Trigo, A., Boëlle-Le Corfec, E., Home, P.D.

“…To describe in type 2 diabetes the 24-hour distribution of hypoglycaemia and compare the frequency of nocturnal events based on a predefined nocturnal window…”
Get full text

Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval by Howe, Matthew D., Britton, K. J., Joyce, H. E., Pappas, G. J., Faust, M. A., Dawson, B. C., Riddle, M. C., Salloway, S. P.

“…Aducanumab is the first FDA-approved amyloid-lowering immunotherapy for Alzheimer’s disease. There is little real-world data to guide management of…”
Get full text

A model for the apparent decrease in optical transmittance of the diabetic eye by Daley, M.L., Watzke, R.C., Riddle, M.C.

“…The authors compare observed changes of ocular transmittance at short and long wavelengths in diabetic patients with values predicted by a model base on the…”
Get full text

Visual flicker discrimination in diabetes by Daley, M.L., Riddle, M.C.

Get full text

The effects of subject-selected high carbohydrate, low fat diets on glycemic control in insulin dependent diabetes mellitus by Hollenbeck, CB, Riddle, MC, Connor, WE, Leklem, JE

“…In the present study, six women with insulin dependent diabetes mellitus (IDDM) were assigned to begin either a control diet containing 45% of the calories as…”
Get full text